On August 13, 2026, in Stoughton, Massachusetts, Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a prominent biopharmaceutical company dedicated to enhancing the lives of individuals dealing with severe and often misconstrued conditions, disclosed its agreement with Jefferies LLC for an Accelerated Share Repurchase (ASR) plan. The agreement involves the repurchase of $50 million worth of the company’s common stock. This ASR is part of the $150 million share repurchase initiative approved by Collegium's Board of Directors in July 2025. Following the completion of this ASR, Collegium will still have $100 million left for repurchases under the program.